QualityStocks would like to highlight CytoSorbents Corporation (OTCBB: CTSO), a critical care-focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption.
In the company’s news last week,
CytoSorbents announced the presentation of data from its research collaboration at the Annual Meeting of the Western Thoracic Surgical Association in Hawaii.
Dr. David Rabkin, assistant professor of Surgery, Division of Cardiothoracic Surgery at the University of Washington Medical Center in Seattle, Wash., will present the potential future use of CytoSorb® blood purification system to protect the viability of organs donated by patients who are officially dead from irreversible brain injury, but whose organs are still working.
“While the vast majority of organ transplants rely on cadaveric donors, it’s long been appreciated that brain death creates an environment hostile to organ function. This effect is particularly pronounced in the heart where estimates suggest that about 20 percent of potential organ donors are excluded from cardiac donation due to the effects of brain death on cardiac function,” Dr. Rabkin stated in the press release.
“One of the components of the body’s reaction to brain death is a surge in inflammatory cytokines which have been shown in other contexts to importantly depress heart function. Using the CytoSorb hemoadsorption technology in a porcine model we demonstrated that cytokine filtration significantly improves heart function after brain death compared to brain dead animals that did not undergo cytokine filtration. This may have important implications for expanding the cardiac donor pool and reducing the increasing disparity between the supply and demand of hearts for transplantation and warrants further study.”
Dr. Chan said the data demonstrates the harmful effect excessive cytokines have on vital organs, and shows CytoSorb’s ability to protect organ function in a potentially important clinical application.
CytoSorb is currently approved to treat excessive levels of cytokines in the EU.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
